The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization approval of Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
The European Commission has granted marketing authorization for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. Omjjara is the first authorized medicine in the EU for disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or... […]
FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy.
Tempus has added a novel MRD assay, xM, to its testing solutions.
FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.
The United States Patent and Trademark Office, or USPTO issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.
Caris Life Sciences and Flatiron Health have partnered to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
Veracyte, a global cancer diagnostics company, has acquired C2i Genomics, a company combining genomics and AI to create a whole-genome cancer intelligence platform.
The Pancreatic Cancer Action Network, or PanCAN, and the Global Coalition for Adaptive Research formed a strategic alliance to further advance research efforts for pancreatic cancer.
The New York Proton Center and the WiTT Group Inc. formed a strategic partnership to help patients navigate the non-clinical challenges of cancer treatment.
